Federal authorities have announced a $24 million civil fraud settlement involving a Dallas laboratory and certain owners and investors over alleged misconduct tied to COVID-19 testing. The resolution is a notable reminder that pandemic-era billing practices remain a live enforcement priority, especially where the government believes testing claims were inflated, medically unnecessary, or otherwise noncompliant.

Although the matter was resolved through settlement rather than a litigated judgment, the size of the payment underscores how aggressively the Department of Justice continues to use civil fraud tools in the healthcare space.